Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma

Hepato-Gastroenterology

Volumn 54, Issue 77, 2007, Pages 1339-1344

  Ailawadhi, Sikander ^a   Nagase, Hiroki ^a   Khoury, Thaer ^a   Yu, Jihnhee ^a   Tan, Dongfeng ^a   Black, Jennifer ^a   Brattain, Michael ^a   Javle, Milind ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cholangiocarcinoma; Epidermal Growth Factor Receptor (EGFR); Mitogen Activated Protein Kinase (MAPK Erk); Signaling proteins; Trefoil Factor

Indexed keywords

CYCLOOXYGENASE 2; INTESTINAL TREFOIL FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PROTEIN KINASE B; STAT PROTEIN;

ADULT; AGED; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES;

EID: 34547645578     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Wright NA, Hoffmann W, Otto WR, Rio MC, Thim L: Rolling in the clover: trefoil factor family (TFF)-domain peptides. FEBS Lett 1997; 408(2):121-123 .
2. Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P, Chambon P: Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acid Res 1984; 12(6):2861-2878.
3. Nunez AM, Jakowlev S, Briand JP, Gaire M, Krust A, Rio MC, Chambon P: Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology 1987; 121(5):1759-1765.
4. Beck S, Schmitt H, Shizuya H, Blin N, Gott P: Cloning of contiguous genomic fragments from human chromosome 21 harbouring three trefoil peptide genes. Hum Genet 1996; 98(2):233-235.
5. De A, Brown DG, Gorman MA, Carr M, Sanderson MR, Freemont PS: Crystal structure of a disulfide-linked "trefoil" motif found in a large family of putative growth factors. Proc Natl Acad Sci USA 1994; 91(3):1084-1088.
6. Jorgensen KH, Thim L, Jacobsen HE: Pancreatic spasmolytic polypeptide (PSP): I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas. Regul Pept 1982; 3(34):207-219.
7. Tomasetto C, Rio MC, Gautier C, Wolf C, Hareuveni M, Chambon P, Lathe R: hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma. EMBO J 1990; 9(2):407-414.
8. Schmitt H, Wundrack I, Beck S, Gott P, Welter C, Shizuya H, Simon MI, Blin N: A third P-domain peptide gene (TFF3), human intestinal trefoil factor maps to 21q22.3as. Cytogenet Cell Genet 1996; 72(4):299-302.
9. Suemori S, Lynch-Devaney K, Podolsky DK: Identification and characterization of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein family. Proc Natl Acad Sci USA 1991; 88(24):11017-11021.
10. Babyatsky MW, deBeaumont M, Thim L, Podolsky DK: Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 1996; 110:489-497.
11. Mashimo H, Wu DC, Podolsky DK, Fishman MC: Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor (see comments). Science 1996; 274:262-265.
12. Dignass A, Lynch-Devaney K, Kindon H, Thim L, Podolsky DK: Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest 1994; 94:376-383.
13. Kindon H, Pothoulakis C, Thim L, Lynch-Devaney K, Podolsky DK: Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology 1995; 109:516-523.
14. Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, Hattori T, Wright NA, Bodmer WF, Pignatelli M: Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Nat Acad Sci USA 1998; 95:3122-3127.
15. Colombel M, Dante R, Bouvier R, Ribieras S, Pangaud C, Marechal JM, Lasne Y: Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue. J Urol 1999; 162(3(pt 1)):927-930.
16. Emami S, Le Floch N, Bruyneel E, Thim L, May F, Westley B, Rio M, Mareel M, Gespach C: Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J 2001; 15(2):351-361.
17. Hanby AM, Poulsom R, Elia G, Singh S, Longcroft JM, Wright NA: The expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in 'gastric metaplasia' of the proximal duodenum: implications of the nature of 'gastric metaplasia'. J Pathol 1993; 169(3):355-360.
18. Hoffmann W, Jagla W, Wiede A: Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol 2001; 16(1):319-334.
19. Labouvie C, Machado JC, Carneiro F, Sarbia M, Vieth M, Porschen R, Seitz G, Blin N: Differential expression of mucins and trefoil peptides in native epithelium, Barrett's metaplasia and squamous cell carcinoma of the oesophagus. J Cancer Res Clin Oncol 1999; 125(2):71-76.
20. May FE, Westley BR: Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J Pathol 1997; 182(4):404-413.
21. Rio MC, Bellocq JP, Daniel JY, Tomasetto C, Lathe R, Chenard MP, Batzenschlager A, Chambon P: Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 1988; 241(4866):705-708.
22. Shaoul R, Marcon MA, Okada Y, Cutz E, Forstner G: Gastric metaplasia: a frequently overlooked feature of duodenal biopsy specimens in untreated celiac disease. J Pediatr Gastroenterol Nutr 2000; 30(4):397-403.
23. Shaoul R, Marcon P, Okada Y, Cutz E, Forstner G: The pathogenesis of duodenal gastric metaplasia: the role of local goblet cell transformation. Gut 2000; 46(5):632-638.
24. Taupin D, Ooi K, Yeomans N, Giraud A: Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Lab Invest 1996; 75(1):25-32.
25. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR: Characterization of gene expression profiles in intraductal pappilary-mucinous tumors of the pancreas. Am J Pathol 2002; 160(5):1745-1754.
26. Warson C, Van De Bovenkamp JH, Korteland-Van Male AM, Buller HA, Einerhand AW, Ectors NL, Dekker J: Barrett's esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2) but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum Pathol 2002; 33(61:660-668.
27. Yeh TS, Jan YY, Chiu CT, Ho YB, Chen TC, Lee KF, Chan KM, Hsu JC, Hwang TL, Chen MF: Characterization of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma. Gut 2002; 51(5):712-716.
28. Nozaki I, Lunz JG 3rd, Specht S, Park JI, Giraud AS, Murase N, Demetris AJ: Regulation and function of trefoil factor family 3 expression in the biliary tree. Amer J Pathol 2004; 165(6):1907-1920.
29. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, Malki S, Alderman BM, Grail D, Hollande F, Heath JK, Ernst M: Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice.(see comment). Nat Med 2002; 8(10):1089-1097.
30. Rodrigues S, Attoub S, Nguyen QD, Bruyneel E, Rodrigue CM, Westley BR, May FE, Thim L, Mareel M, Emami S, Gespach C: Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells. Oncogene 2003; 22(29):4488-4497.
31. Hambek M, Baghi M, Strebhardt K, May A, Adunka O, Gstottner W, Knecht R: STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR. (erratum appears in Anticancer Res. 2005 Jan-Feb;25(1b):681 Note: Strebhard, Klaus (corrected to Strebhardt, Klaus)). Anticancer Res 2004; 24(6):3881-3886.
32. Tadlock L, Patel T: Involvement of p38 mitogen-activated protein kinase signaling signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology 2001; 33(1):43-51.
33. Sirica AE, Lai GH, Zhang Z: Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 2001; 16(4):363-372.
34. Zhang Z, Lai GH, Sirica AE: Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004; 39(4):1028-1037.
35. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ: Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002; 122(4):985-993.
36. Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, Bacus S, Brattain MG, Kreisberg JI, Hidalgo M: Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.(see comment). Clin Cancer Res 2003; 9(7):2478-2486.
37. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, Geradts J, Javle M, Brattain M: Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004; 8(4):448-453.
38. Khoury T, Chadha K, Javle M, Donohue K, Levea C, Iyer R, Okada H, Nagase H, Tan D: Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma. Int J Gastrointest Cancer 2005; 35(3):171-177.
39. Vauthey JN, Blumgart LH: Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14:109.
40. Carriaga MT, Henson DE: Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75(suppl 1):171-190.
41. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH: Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998; 228:385-394.
42. Anderson C, Pinson W, Berlin J, Chari R: Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9:43-57.
43. Johnson GL, Vaillancourt RR: Sequential protein kinase reactions controlling cell growth and differentiation. Curr Opin Cell Biol 1994; 6(2):230-238.
44. Cano E, Mahadevan LC: Parallel signal processing among mammalian MAPKs. Trends Bioehem Sci 1995; 20(3):117-122.
45. Kang W, Nielsen O, Fenger C, Madsen J, Hansen S, Tornoe I, Eggleton P, Reid KB, Holmskov U: The scavenger receptor, cysteine-rich domain-containing molecule gp-340 is differentially regulated in epithelial cell lines by phorbol ester. Clin Exp Immunol 2002; 130(3):449-458.
46. Kang W, Nielsen O, Fenger C, Leslie G, Holmskov U, Reid KB: Induction of DMBT1 expression by reduced Erk activity during a gastric mucosa differentiation-like process and its association with human gastric cancer. Carcinogenesis 2005; 26(6):1129-1137.
47. Leung WK, Yu J, Chan FK, To KF, Chan MW, Ebert MP, Ng EK, Chung SC, Malfertheiner P, Sung JJ: Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol 2002; 197(5):582-588.
48. Kanai M, Mullen C, Podolsky DK: Intestinal trefoil factor induces inactivation of extracellular signal-regulated protein kinase in intestinal epithelium. Proc Natl Acad Sci 1995; 95:178-182.